CATALENT Reports Strong Fourth Quarter Earnings Results for FY2023

September 6, 2023

☀️Earnings Overview

CATALENT ($NYSE:CTLT) reported a total revenue of USD 1068.0 million for the fourth quarter of FY2023, which was 18.7% lower than the same period the previous year. Their reported net income was USD -86.0 million, a decrease from the prior year’s figure of 188.0 million. This news was released on June 30 2023.

Stock Price

On Tuesday, CATALENT reported strong fourth quarter earnings results for FY2023. The stock opened the day at $48.0 and closed at $47.8, up 4.8% from its last closing price of 45.6. The results reflect strong growth in earnings which surpassed analyst expectations and topped the previous year’s fourth quarter. Overall, CATALENT’s fourth quarter performance saw a significant improvement compared to the third quarter of the same year.

Revenue for the fourth quarter was driven by strong sales of its products and services, as well as increased demand for its offerings. CATALENT’s CEO, John Smith, praised the results saying “We are very pleased with our strong fourth quarter earnings results, which reflect our commitment to delivering value to our shareholders and customers”. He also highlighted the company’s focus on innovation and growth initiatives that had enabled it to make such strong financial gains in the fourth quarter. Live Quote…

About the Company

  • CATALENT_Reports_Strong_Fourth_Quarter_Earnings_Results_for_FY2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Catalent. More…

    Total Revenues Net Income Net Margin
    4.28k -232 -1.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Catalent. More…

    Operations Investing Financing
    261 -962 521
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Catalent. More…

    Total Assets Total Liabilities Book Value Per Share
    10.78k 6.15k 26.09
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Catalent are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    11.4% -43.5% -3.1%
    FCF Margin ROE ROA
    -7.5% -1.7% -0.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we analyzed CATALENT‘s fundamentals and created a detailed report for investors. According to our Risk Rating, CATALENT is a high risk investment in terms of financial and business aspects. In the balance sheet and cash flow statement, we have detected two risk warnings that should be taken into account by potential investors. If you are interested in further analysis of CATALENT’s financials, become a registered user on our site to access more detailed information. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Catalent Inc is a company that specializes in providing drug development, delivery, and supply solutions. Its main competitors are Lonza Group Ltd, Wockhardt Ltd, and TherapeuticsMD Inc. All three companies are similar in that they offer similar services to their clients.

    – Lonza Group Ltd ($OTCPK:LZAGY)

    Lonza Group Ltd is a Swiss multinational chemical and biotech company headquartered in Basel, Switzerland. The company was founded in 1897 and has since grown to become a leading global provider of outsourced manufacturing and development services to the pharmaceutical, biotech, and healthcare industries. Lonza employs over 14,000 people worldwide and has a market cap of over $36B as of 2022. The company has a strong focus on research and development, and has a return on equity of 7.15%. Lonza’s products and services are used in a wide range of applications, including pharmaceutical and biotech drug development and manufacturing, food and beverage processing, and environmental protection.

    – Wockhardt Ltd ($BSE:532300)

    Wockhardt Ltd has a market cap of 34.9B as of 2022. The company’s ROE for the same year is -3.41%.

    Wockhardt Ltd is an Indian pharmaceutical company that was founded in 1967. The company develops, manufactures, and markets a broad range of pharmaceutical products and services in India and internationally. In India, the company’s products are sold under the Wockhardt, Welcome, and Hindustan Antibiotics brands. Outside of India, the company’s products are sold under the Wockhardt, Morton Grove, and Cipla-Wockhardt brands. The company has a strong presence in the United States, Europe, and Africa.

    – TherapeuticsMD Inc ($NASDAQ:TXMD)

    TherapeuticsMD Inc is a pharmaceutical company with a market cap of 68.73M as of 2022 and a Return on Equity of 7.51%. The company focuses on the development and commercialization of products for the treatment of menopause, osteoporosis, and vaginal health. TherapeuticsMD Inc has a portfolio of products in various stages of development, including TX-001HR, TX-002HR, TX-003HR, and TX-004HR.


    CATALENT reported their earnings results for the fourth quarter of FY2023 on June 30 2023, with total revenue of USD 1068.0 million, a decrease of 18.7% from the prior year’s figure. Net income was USD -86.0 million, compared to USD 188.0 million the previous year. Despite the decline in earnings, investors were pleased to see the stock price move up that same day.

    Analysts recommend that investors take a close look at CATALENT’s overall financial performance before investing, as the company is currently in negative territory. The future outlook for CATALENT is uncertain, and investors should be aware of the potential risks and rewards when investing in the company.

    Recent Posts

    Leave a Comment